Partners from Europe and US headed towards Noordwijkerhout to join the 1,5 days Annual meeting of the PlaqOmics consortium. This was the first F2F meeting after the pandemic. We keep you posted about the outcome!
Partners from Europe are heading towards Philadelphia to join the 1,5 days Annual meeting of the PlaqOmics consortium. We keep you posted about the outcome!
Today Gary and Gerard circulated the reviews of the first round of the Young Investigator Grants. Eleven proposals have been submitted for our initial round of Young Investigator Awards. The coordinators were delighted with the number and overall quality of the applications. Final funding decision will be made end of August.
Thromboembolic events secondary to rupture or erosion of advanced atherosclerotic plaques represent the leading cause of death worldwide. However, the mechanisms that regulate plaque stability are poorly understood. The overall hypothesis of our PlaqOmics Network is that detrimental reprogram-ming of smooth muscle cells (SMCs) and other ACTA2+ fibrous cap cells destabilizes atherosclerotic plaques and that there are critical genetic deter-minants of CAD risk that act, in part, by impacting phenotypic transitions of fibrous cap cells.
We are happy to announce that our first progress meeting is starting in 4 days.
We made substantial progress bringing together our PlaqOmics members.
A lot of collaborations have been started and excited new data has been generated.
Today we received the official announcement from the Leducq foundation that "18CVD02: Defining the Roles of Smooth Muscle Cells and Other Extracellular Matrix Producing Cells in Late Stage Atherosclerotic Plaque Pathogenesis" will be funded.
Exciting times ahead of us!
The pre-award meeting took place in Charlottesville. It was an inspiring meeting with almost all PIs and Co-PIs. We discussed logistics of our network as well as scientific goals.
Our first Annual Meeting will take place in Lübeck, Germany on April 8./9. 2019.
F2F meeting of PIs and members of PlaqOmics at Hamburg airport.
The CANTOS Trial: One Important Step for Clinical Cardiology but a Giant Leap for Vascular Biology.